ProShares Ultra NASDAQ Biotechnology
21 hedge funds and large institutions have $6.5M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
62% more call options, than puts
Call options by funds: $752K | Put options by funds: $465K
0% more capital invested
Capital invested by funds: $6.47M → $6.5M (+$26.1K)
0.25% less ownership
Funds ownership: 7.53% → 7.28% (-0.25%)
13% less funds holding
Funds holding: 24 → 21 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$711K |
| 2 |
WWM
Westwood Wealth Management
Los Angeles,
California
|
+$258K |
| 3 |
Jane Street
New York
|
+$24.1K |
| 4 |
TC
Truvestments Capital
Sarasota,
Florida
|
+$8.07K |
| 5 |
Morgan Stanley
New York
|
+$6.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$535K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$457K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$229K |
| 4 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$100K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$77.5K |
BIB Hedge Fund Activity: Q3 2024 in Review
21 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2024, worth a combined $6.5M — up 0.4% from $6.47M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIB and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was IMC Chicago, adding an estimated $711K. The largest seller was Tower Research Capital (TRC), cutting an estimated $535K.
- 21 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2024, down from 24 in Q2 2024.
- Funds reported $6.5M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2024, up 0.4% quarter-over-quarter.
- 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2024 and 5 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2024 was IMC Chicago, an estimated $711K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2024 was Tower Research Capital (TRC), an estimated $535K sold.
Based on aggregated 13F filings for Q3 2024.